Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 2
2006 14
2007 17
2008 17
2009 17
2010 23
2011 31
2012 29
2013 32
2014 20
2015 21
2016 30
2017 39
2018 29
2019 37
2020 35
2021 38
2022 37
2023 27
2024 40
2025 26
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

505 results

Results by year

Filters applied: . Clear all
Page 1
Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease.
Cho MS, Kang DY, Ahn JM, Yun SC, Oh YS, Lee CH, Choi EK, Lee JH, Kwon CH, Park GM, Choi HO, Park KH, Park KM, Hwang J, Yoo KD, Cho YR, Kim JH, Hwang KW, Jin ES, Kwon O, Kim KH, Park SJ, Park DW, Nam GB; EPIC-CAD Investigators. Cho MS, et al. Among authors: park dw. N Engl J Med. 2024 Dec 5;391(22):2075-2086. doi: 10.1056/NEJMoa2407362. Epub 2024 Sep 1. N Engl J Med. 2024. PMID: 39225258 Clinical Trial.
Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial.
Park SJ, Ahn JM, Kang DY, Yun SC, Ahn YK, Kim WJ, Nam CW, Jeong JO, Chae IH, Shiomi H, Kao HL, Hahn JY, Her SH, Lee BK, Ahn TH, Chang KY, Chae JK, Smyth D, Mintz GS, Stone GW, Park DW; PREVENT Investigators. Park SJ, et al. Among authors: park dw. Lancet. 2024 May 4;403(10438):1753-1765. doi: 10.1016/S0140-6736(24)00413-6. Epub 2024 Apr 8. Lancet. 2024. PMID: 38604213 Clinical Trial.
Left Main Disease.
Lee J, Park DW, Park SJ. Lee J, et al. Among authors: park dw. Interv Cardiol Clin. 2022 Oct;11(4):359-371. doi: 10.1016/j.iccl.2022.02.006. Epub 2022 Sep 24. Interv Cardiol Clin. 2022. PMID: 36243482 Review.
Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study).
Giacoppo D, Alfonso F, Xu B, Claessen BEPM, Adriaenssens T, Jensen C, Pérez-Vizcayno MJ, Kang DY, Degenhardt R, Pleva L, Baan J, Cuesta J, Park DW, Schunkert H, Colleran R, Kukla P, Jiménez-Quevedo P, Unverdorben M, Gao R, Naber CK, Park SJ, Henriques JPS, Kastrati A, Byrne RA. Giacoppo D, et al. Among authors: park dw. Eur Heart J. 2020 Oct 7;41(38):3715-3728. doi: 10.1093/eurheartj/ehz594. Eur Heart J. 2020. PMID: 31511862 Free PMC article.
Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis.
Sabatine MS, Bergmark BA, Murphy SA, O'Gara PT, Smith PK, Serruys PW, Kappetein AP, Park SJ, Park DW, Christiansen EH, Holm NR, Nielsen PH, Stone GW, Sabik JF, Braunwald E. Sabatine MS, et al. Among authors: park dw. Lancet. 2021 Dec 18;398(10318):2247-2257. doi: 10.1016/S0140-6736(21)02334-5. Epub 2021 Nov 15. Lancet. 2021. PMID: 34793745 Review.
Preventive PCI or medical therapy alone for vulnerable atherosclerotic coronary plaque: Rationale and design of the randomized, controlled PREVENT trial.
Ahn JM, Kang DY, Lee PH, Ahn YK, Kim WJ, Nam CW, Jeong JO, Chae IH, Shiomi H, Kao PHL, Hahn JY, Her SH, Lee BK, Ahn TH, Chang K, Chae JK, Smyth D, Stone GW, Park DW, Park SJ; PREVENT Investigators. Ahn JM, et al. Among authors: park dw. Am Heart J. 2023 Oct;264:83-96. doi: 10.1016/j.ahj.2023.05.017. Epub 2023 Jun 2. Am Heart J. 2023. PMID: 37271356
The burden of cardiovascular disease in Asia from 2025 to 2050: a forecast analysis for East Asia, South Asia, South-East Asia, Central Asia, and high-income Asia Pacific regions.
Goh RSJ, Chong B, Jayabaskaran J, Jauhari SM, Chan SP, Kueh MTW, Shankar K, Li H, Chin YH, Kong G, Anand VV, Chan KA, Sukmawati I, Toh SA, Muthiah M, Wang JW, Tse G, Mehta A, Fong A, Baskaran L, Zhong L, Yap J, Yeo KK, Hausenloy DJ, Tan JWC, Chao TF, Li YH, Lim SL, Chan KH, Loh PH, Chai P, Yeo TC, Low AF, Lee CH, Foo R, Tan HC, Yip J, Rao S, Honda S, Yasuda S, Kajiya T, Goto S, Yan BP, Zhou X, Figtree GA, Mamas MA, Kim Y, Jeong YH, Kim MH, Park DW, Park SJ, Richards AM, Chan MY, Lip GYH, Chew NWS. Goh RSJ, et al. Among authors: park dw. Lancet Reg Health West Pac. 2024 Jul 10;49:101138. doi: 10.1016/j.lanwpc.2024.101138. eCollection 2024 Aug. Lancet Reg Health West Pac. 2024. PMID: 39100533 Free PMC article.
Optical Coherence Tomography-Guided or Intravascular Ultrasound-Guided Percutaneous Coronary Intervention: The OCTIVUS Randomized Clinical Trial.
Kang DY, Ahn JM, Yun SC, Hur SH, Cho YK, Lee CH, Hong SJ, Lim S, Kim SW, Won H, Oh JH, Choe JC, Hong YJ, Yoon YH, Kim H, Choi Y, Lee J, Yoon YW, Kim SJ, Bae JH, Park DW, Park SJ; OCTIVUS Investigators. Kang DY, et al. Among authors: park dw. Circulation. 2023 Oct 17;148(16):1195-1206. doi: 10.1161/CIRCULATIONAHA.123.066429. Epub 2023 Aug 27. Circulation. 2023. PMID: 37634092 Clinical Trial.
505 results